Pfizer does not anticipate federal regulatory approval of ritlecitinib until at least 2023, according to the company’s December 2021 presentation to investors.
https://www.politifact.com/factchecks/2022/mar/31/facebook-posts/evidence-does-not-support-claim-pfizer-staged-osca/
Pfizer does not anticipate federal regulatory approval of ritlecitinib until at least 2023, according to the company’s December 2021 presentation to investors.
(post is archived)